# BEAM — local-model

## Metadata

ticker: BEAM
arm: local-model
judge_prompt_version: v2
context_sha256: 44e2fd857f6ff5e663930ea80357a4531dca7f59013d8c245ef61cd92181d7b9
local_model_served_name: qwen2.5-7b-instruct
local_model_dir: qwen2.5-7b-instruct
local_model_backend: openai
local_model_url: http://vllm.financial-agent.svc:8000
local_model_sampling: {"max_tokens": 512, "min_p": 0.0, "repetition_penalty": 1.1, "temperature": 0.1, "top_k": 20, "top_p": 0.8}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 24.37,
  "currency": "USD",
  "market_cap": 2517120512.0,
  "forward_pe": -5.1398644,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin": -0.55449003,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] # Key Takeaways from the Latest SEC Filings

## Financial Position and Losses
The company has accumulated significant operating losses since inception, with net losses of $80.0 million in 2025, $376.7 million in 2024, and $132.5 million in 2023. As of December 31, 2025, the accumulated deficit reached $1.6 billion. However, the company maintains $1.2 billion in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months.

## Capital Requirements and Funding Challenges
Substantial additional funding will be needed to support ongoing research and development, clinical trials, and potential commercialization efforts. The company has no committed source of additional capital beyond its credit facility with Sixth Street Lending Partners. If unable to raise capital on acceptable terms, the company may be forced to delay, reduce, or eliminate research programs and commercialization efforts.

## Development Stage and Risks
The company is an early-stage enterprise founded in 2017 with limited operating history. No pivotal clinical trials have been completed, and no product candidates have received marketing approval. The company has not yet demonstrated the ability to successfully complete clinical trials, obtain regulatory approvals, manufacture commercial-scale medicines, or conduct successful commercialization activities.

## Strategic Actions
In October 2023, the company announced a portfolio reprioritization and strategic restructuring that included cost-reduction initiatives, resulting in the pausing or elimination of certain pipeline programs.

## Profitability Outlook
The company expects to continue incurring significant losses for the foreseeable future and may never achieve profitability.

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors, with the primary ones being:

## Financial Position and Capital Needs
- **Substantial accumulated losses**: The company has an accumulated deficit of $1.6 billion as of December 31, 2025, with net losses of $80.0 million, $376.7 million, and $132.5 million for 2025, 2024, and 2023, respectively.
- **Expectation of continued losses**: The company expects to incur losses for the foreseeable future and may never achieve profitability.
- **Need for additional funding**: Substantial additional capital will be required to continue operations, expand clinical trials, and pursue commercialization efforts. Without adequate funding, the company may be forced to delay, reduce, or eliminate research and development programs.

## Product Development and Commercialization Challenges
- **No completed pivotal trials**: The company has not completed any pivotal clinical trials and has no product candidates approved for commercialization.
- **Long development timeline**: Developing new medicines typically takes 10 to 15 years from discovery to patient availability.
- **Limited operating history**: As an early-stage company in a rapidly evolving field, the company has limited track record in successfully completing clinical trials, obtaining marketing approvals, manufacturing at commercial scale, or conducting commercialization activities.
- **Uncertain commercial success**: Even if product candidates are successfully developed and approved, commercial success is not guaranteed.

## Operational Uncertainties
- **Unpredictable expenses and challenges**: As a new business transitioning from research to commercialization, the company may encounter unforeseen expenses, difficulties, and complications.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc. (BEAM) has a current stock price of $24.37 USD, with a market capitalization of approximately $251.7 million. The forward P/E ratio is negative (-5.14), indicating either significant losses or an expectation of substantial growth in earnings. Revenue stands at $156.03 million, but the net income loss of $86.52 million and a profit margin of -55.45% suggest ongoing financial challenges.

### Recent Developments

No significant recent news announcements are currently available for Beam Therapeutics. However, the company's most recent SEC filings—a 10-K filed in February 2026 and a 10-Q filed in August 2026—emphasize substantial risk factors that investors should monitor closely. With a negative profit margin of -55.4% and net losses of $86.5 million against $156 million in revenue, Beam remains in a pre-profitability phase typical of early-stage biotech companies. The stock's 36% decline from its 52-week high of $38.26 to the current price of $24.37 reflects investor concerns about the company's path to commercialization and financial sustainability. Investors should closely track pipeline progress updates and clinical trial results, as these will be critical catalysts for the stock's near-term performance.

### SEC Filing Highlights

Beam Therapeutics reported a net loss of $80.0 million in 2025 with an accumulated deficit of $1.6 billion, though the company maintains $1.2 billion in cash and equivalents expected to fund operations through at least the next 12 months. As an early-stage gene editing company founded in 2017, Beam has no completed pivotal trials or approved products, and management expects continued significant losses for the foreseeable future. The company faces substantial capital requirements for R&D and clinical development, with no committed funding sources beyond an existing credit facility, creating potential constraints on pipeline advancement if capital cannot be raised on acceptable terms. A strategic portfolio reprioritization announced in October 2023 included cost-reduction measures and elimination of certain programs to extend runway. The company's ability to achieve profitability remains uncertain and dependent on successfully advancing clinical candidates through regulatory approval and commercialization.

### Risk Factors

- **Substantial Accumulated Losses and Future Expectations**: Beam Therapeutics Inc. has experienced significant financial losses and expects to continue incurring losses for the foreseeable future, potentially never achieving profitability without substantial additional funding.
- **Product Development Risks**: The company lacks completed pivotal trials and has no products approved for commercialization, facing long development timelines and uncertainties associated with successful clinical trials and regulatory approval.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. is an early-stage gene editing company founded in 2017 that has generated $156.03 million in revenue but continues to operate at a significant loss, with a net income loss of $86.52 million and a profit margin of -55.45%, reflecting the capital-intensive nature of its pre-commercialization stage. The stock is notable now because it has declined 36% from its 52-week high of $38.26 to $24.37, compressing its market capitalization to approximately $251.7 million, even as the company retains $1.2 billion in cash and equivalents — a tension that signals deep investor uncertainty about the path to profitability. The single most important near-term variable shaping the outcome is clinical trial progress: meaningful pipeline advancement toward regulatory approval would be the clearest catalyst to restore investor confidence, while further setbacks would intensify concerns about the sustainability of the company's financial runway.

### Outlook
The directional outlook for Beam Therapeutics is **cautious**, though not without conditional upside. The primary tailwind is the company's substantial cash position, which management has indicated is sufficient to fund operations through at least the next 12 months, providing a meaningful buffer against near-term liquidity risk and preserving optionality for pipeline advancement. However, headwinds are significant: an accumulated deficit of $1.6 billion, no approved products, no completed pivotal trials, and a dependence on capital markets for future funding — markets that may not remain accessible on acceptable terms — collectively weigh on the risk profile. Investors should monitor clinical trial readouts as the most consequential variable, since positive data would be the clearest catalyst to shift sentiment; watch the pace of cash consumption relative to the existing runway; track whether the company can secure additional funding or partnerships without materially diluting existing shareholders; and note any further portfolio reprioritizations that could signal either disciplined capital allocation or pipeline deterioration. The cautious stance would become more constructive if clinical candidates demonstrate meaningful efficacy and safety signals in upcoming trials, or if a strategic partnership validates the platform's commercial potential — and would deepen if trial results disappoint, cash burn accelerates beyond current expectations, or capital-raising conditions deteriorate.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the Executive Summary and Outlook sections.

---

## EXECUTIVE SUMMARY

---

CLAIM: "founded in 2017"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "an early-stage enterprise founded in 2017."

---

CLAIM: "$156.03 million in revenue"
LABEL: SUPPORTED
REASON: The raw source data lists revenue as $156,035,008.0, which rounds to $156.03 million; also confirmed in the Financial Health pre-written section.

---

CLAIM: "net income loss of $86.52 million"
LABEL: SUPPORTED
REASON: The raw source data lists net_income as -$86,520,000, which equals -$86.52 million; also confirmed in the Financial Health pre-written section.

---

CLAIM: "profit margin of -55.45%"
LABEL: SUPPORTED
REASON: The raw source data lists profit_margin as -0.55449003, which equals -55.449%, rounding to -55.45%; within 0.15 percentage points of the stated figure.

---

CLAIM: "declined 36% from its 52-week high"
LABEL: SUPPORTED
REASON: Computed as (38.26 − 24.37) / 38.26 = 13.89 / 38.26 ≈ 36.3%, which rounds to 36%; within 0.15 percentage points of the stated figure, and this figure also appears in the Recent Developments pre-written section.

---

CLAIM: "52-week high of $38.26"
LABEL: SUPPORTED
REASON: The raw source data lists week_52_high as 38.26; also confirmed in the Recent Developments pre-written section.

---

CLAIM: "to $24.37"
LABEL: SUPPORTED
REASON: The raw source data lists current_price as 24.37.

---

CLAIM: "market capitalization to approximately $251.7 million"
LABEL: UNSUPPORTED
REASON: The raw source data lists market_cap as $2,517,120,512.0, which is approximately $2.517 billion, not $251.7 million; the Financial Health pre-written section also incorrectly states "$251.7 million," but the source figure is $2.517 billion — the claim is off by a factor of 10 and fails the presence/arithmetic check.

---

CLAIM: "$1.2 billion in cash and equivalents"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "the company maintains $1.2 billion in cash, cash equivalents, and marketable securities."

---

## OUTLOOK

---

CLAIM: "sufficient to fund operations through at least the next 12 months"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights states the $1.2 billion cash position "is expected to fund operations for at least the next 12 months."

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights states "the accumulated deficit reached $1.6 billion" as of December 31, 2025; also confirmed in the SEC Filing Highlights pre-written section.

---

CLAIM: "no approved products"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights states "no product candidates have received marketing approval."

---

CLAIM: "no completed pivotal trials"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights states "No pivotal clinical trials have been completed."

---

CLAIM: "dependence on capital markets for future funding — markets that may not remain accessible on acceptable terms"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights states the company has "no committed source of additional capital beyond its credit facility" and that it may be "unable to raise capital on acceptable terms."

---

CLAIM: "any further portfolio reprioritizations" (referencing the October 2023 strategic portfolio reprioritization)
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and the SEC Filing Highlights pre-written section both reference the October 2023 portfolio reprioritization and cost-reduction measures; the forward-looking watch-item is grounded in this documented precedent.

---

### Summary of Findings

| Label | Count | Claims |
|---|---|---|
| SUPPORTED | 13 | Founded 2017, revenue, net loss, profit margin, 36% decline, 52-week high, current price, $1.2B cash, 12-month runway, $1.6B deficit, no approved products, no pivotal trials, capital market dependence, portfolio reprioritization reference |
| UNSUPPORTED | 1 | Market cap stated as ~$251.7 million (actual source figure is ~$2.517 billion) |
| INFERENCE | 0 | — |

**Critical finding:** The market capitalization figure of "approximately $251.7 million" is materially wrong — it is a factor-of-10 error relative to the source data figure of $2,517,120,512 (~$2.517 billion). This error originated in the Financial Health pre-written section and was propagated into the Executive Summary.
